Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Clinical Trials: Anxiety Disorders
A listing of clinical trials currently looking for volunteers to enroll in Anxiety Disorders studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Forest Investigative Site 001
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Birmingham : Birmingham Research Group, Inc
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
California
Beverly Hills : Forest Investigative Site 021
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Carson : Dr. Joseph H. Rodd
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Glendale : Forest Investigative Site 023
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Imperial : Sun Valley Research
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Irvine : Irvine Center for Clinical Research
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
View More »
Paramount : Forest Investigative Site 011
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
San Diego : University of California, San Diego
Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
San Diego : Sharp Mesa Vista Hospital, Clinical Research Department
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Wildomar : Elite Clinical Trials, Inc
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Connecticut
Norwich : Forest Investigative Site 026
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Waterbury : Forest Investigative Site 027
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
District of Columbia
Washington : US003
Pharmacokinetics and Tolerability of Lu AA21004 in Child and Adolescent Patients With Depressive or Anxiety Disorder
Florida
Bradenton : Florida Clinical Research Center
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Delray Beach : Forest Investigative Site 005
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Gainsville : Sarkis Clinical Trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Oakland Park : Forest Investigative Site 014
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
South Miami : Forest Investigative Site 019
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
View More »
Winter Park : Kolin Research Group
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Georgia
Decatur : Forest Investigative Site 035
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Smyrna : Institute of Behavioral Medicine, LLC
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Illinois
Chicago : Forest Investigative Site 028
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Schaumburg : Forest Investigative Site 030
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Kansas
Topeka : Forest Investigative Site 029
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Wichita : US004
Pharmacokinetics and Tolerability of Lu AA21004 in Child and Adolescent Patients With Depressive or Anxiety Disorder
Wichita : Forest Investigative Site 033
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Louisiana
Lake Charles : Lake Charles Clinical Trials
Safety and Tolerability of SPD503 in Subjects Aged 6 - 17 Years with Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
View More »
Lake Charles : Forest Investigative Site 010
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Lake Charles : Lake Charles Clinical Trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Michigan
Birmingham : Vision Specialists of Birmingham
Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria
Rochester Hills : Rochester Center for Behavioral Medicine
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Missouri
St Charles : Midwest Research Group
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Nebraska
Lincoln : Premier Psychiatric Group, LLC
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Nevada
Las Vegas : Center for Psychiatry and Behavioral Medicine, Inc
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
New Jersey
Berlin : Forest Investigative Site 016
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Cherry Hill : Center for Emotional Fitness
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
New York
New York : The Rockefeller University Hospital
Effect of Metabolic State on Anxiety in Human Subjects
View More »
Brooklyn : Forest Investigative Site 007
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
New York : Weill Cornell Medical College
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
New York : Forest Investigative Site 032
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
New York : Forest Investigative Site 012
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
New York : Forest Investigative Site 024
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
New York : The Medical Research Network, LLC
Study of Vilazodone to Treat Social Anxiety Disorder
Rochester : Finger Lakes Clinical Research
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Staten Island : Richmond Behavioral Associates
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
North Carolina
Durham : Duke University Medical Center, Duke Child and Family Study Center
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
North Dakota
Bismarck : Forest Investigative Site 020
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Ohio
Cincinnati : Forest Investigative Site 008
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Cincinnati : University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Cincinnatti : US002
Pharmacokinetics and Tolerability of Lu AA21004 in Child and Adolescent Patients With Depressive or Anxiety Disorder
Cleveland : University Hospitals of Cleveland Medical Center
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Dayton : Forest Investigative Site 041
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
View More »
Middleburg Heights : North Star Research
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Oklahoma
Oklahoma City : Forest Investigative Site 004
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Oklahoma City : Forest Investigative Site 034
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Oklahoma City : IPS Research Company
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Oregon
Portland : Summit Research Network (Oregon), Inc.
Anxiety Clinical Research Study
View More »
Portland : Forest Investigative Site 013
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Tennessee
Memphis : Forest Investigative Site 006
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Memphis : Research Strategies of Memphis, LLC
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Texas
Austin : FutureSearch Clinical Trials, LP
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Houston : Houston Clinical Trials LLC
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Wichita Falls : Forest Investigative Site 017
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Utah
Salt Lake City : Optimum Clinical Research, Inc.
Irritable Bowel Syndrome - Diarrhea Predominant
View More »
Clinton : Ericksen Research and Development
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Salt lake City : Forest Investigative Site 003
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Virginia
Charlottesville : Forest Investigative Site 018
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Herndon : NeuroScience, Inc.
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Washington
Bellevue : Northwest Clinical Research Center
Post Traumatic Stress Disorder (PTSD)
Seattle : Summit Research Network (Seattle) LLC
Anxiety Clinical Research Study
View More »
Bellevue : Forest Investigative Site 040
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Seattle : Forest Investigative Site 039
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Austria
Graz : Site Ref # / Investigator 64830
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (Relax)
Innsbruck : Site Ref # / Investigator 64832
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (Relax)
Linz : Site Ref # / Investigator 64829
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (Relax)
Salzburg : Site Ref # / Investigator 64831
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (Relax)
St. Veit/Glan : Site Ref # / Investigator 79613
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (Relax)
View More »
Vienna : Site Ref # / Investigator 64833
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (Relax)
Vienna : Site Ref # / Investigator 47342
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab (Relax)
Brazil
Fortaleza : Unidade de Farmacologia Clínica - UNIFAC
Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety
Sao Paulo : SPDM - Associação Paulista para o Desenvolvimento da Medicina - Hospital São Paulo
Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety
Bulgaria
Bourgas : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Rousse : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Varna : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Canada
Hamilton : McMaster University Medical Centre
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
Ottawa : The University of Ottawa Institute of Mental Health Research
Cipralex® for Anxiety Disorders in Adolescents
Toronto : Holland Orthopaedic and Arthritic Centre
Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery
Toronto, : START Clinic for Mood and Anxiety Disorders 900-790 Bay St.
An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia
China
Shanghai : Shanghai Tongji Hospital
Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder
Denmark
Hungary
Baja : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Baja N/A : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Budapest : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Kalocsa : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
India
Ahmedabad : Sheth V S General Hospital
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
Bangalore : Spandana Nursing Home
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
Hyderabad : Asha Hospital
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
Lucknow : Manobal Medical Research Centre
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
Mysore : JSS Medical College Hospital
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
View More »
Pune : Poona Hospital & Research Centre
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
Shimoga : Sridhar Neuro Psychiatric Center
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
Romania
Arad : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Iasi : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Russian Federation
Moscow : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Nizny Novgorod : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Saratov : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
St-Peterburg : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
St-Petersburg : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
View More »
Tomsk : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Ukraine
Donetsk : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Glevakha : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Kharkiv : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Kiev : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
Odessa : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
View More »
Village Stepanovka Kherson : Updated
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
